After a seven day jury trial, the jury unanimously decided that the SOLiD sequencing technology did not infringe the patent.
“We are very pleased with the decisions by the Court and the jury in this action,” said Kip Miller, president, Genetic Systems Division at Life Technologies. “The SOLiD™ sequencing platform was developed through substantial R&D efforts within Applied Biosystems. These decisions validate our belief that the SOLiD™ sequencing system is unique in its design and paves the way for us to continue building on its innovative design and superlative performance with the upcoming launch of SOLiD 3.0 this February.”